Nucro-Technics
Acquisition in 2023
Nucro-Technics is a contract research organization that specializes in providing comprehensive support to the pharmaceutical, biologic, and medical device industries. The company offers a range of services, including clinical trial support, analytical chemistry testing, microbiology testing, toxicology services, bioanalytical services, genetic toxicology, and medical device testing. By partnering with various companies in these sectors, Nucro-Technics aims to facilitate product development and ensure compliance with regulatory requirements through its expert consulting and testing capabilities.
Heyan Biotech
Acquisition in 2021
Heyan Biotech is a national biotech industry base, provides for target based in vitro pharmacodynamic screening and early pharmacological pharmacodynamic evaluation services in early drug discovery.
Ocean Ridge Biosciences
Acquisition in 2021
Ocean Ridge Biosciences is a life science company based in Deerfield Beach, Florida, specializing in genomic services for the healthcare and life science sectors. The company focuses on the extraction and analysis of RNA and proteins from a diverse range of biological samples, utilizing a real-time PCR platform. This innovative approach enables researchers to make informed, data-driven decisions. As demand for high-quality genomic services continues to rise in both research and clinical applications, Ocean Ridge Biosciences aims to provide accurate and affordable solutions to meet the needs of its clients in the evolving landscape of biotechnology.
Acme Bioscience
Acquisition in 2020
Acme Bioscience is a biological research and development organization located in Palo Alto, California, dedicated to serving biopharmaceutical companies globally. The company specializes in discovery chemistry, medicinal chemistry, process chemistry research and development, and chemical manufacturing services. Acme Bioscience has significant expertise in antiviral and antibacterial research, as well as in the development of nucleotides, nucleosides, triphosphates pro-drugs, heterocycles, and boron-containing compounds. Through its custom synthesis and process research capabilities, the company assists clients in addressing complex medicinal challenges. Additionally, Acme Bioscience offers consulting services for chronic mucocutaneous candidiasis and provides various biological tests and analytical services, including X-ray analysis, ensuring comprehensive support for its customers in the development of new chemical entities.
Concord Biosciences
Acquisition in 2018
Concord Biosciences is a provider of contract research and chemical development services that supports drug candidate development from lead identification to regulatory submission. The company offers a comprehensive suite of non-clinical discovery support and integrated R&D services, including early pharmacokinetic and metabolism screening, pilot toxicology evaluations, and IND/NDA-enabling toxicology and DMPK development for both small molecules and biologics. Additionally, Concord Biosciences provides synthetic, medicinal, and process chemistry, radiochemistry, and cGMP API manufacturing, catering to both small-scale clinical batches and commercial API production. With a research site located in Concord, Ohio, the company’s experienced scientists deliver expertise and services designed to shorten the time to IND and facilitate the progression of drug candidates to clinical trials. By offering integrated scientific capabilities, Concord Biosciences aims to provide high-value development programs that encompass all phases of drug development.
BDM Consulting
Acquisition in 2015
BDM Consulting is an independent CRO specializing in biostatistics. SAS programming, and data management. BDM is composed of a group of more than 35 critical talents/experts, who excel and stand out among their peers in the industry. Its clients and partners include pharmaceutical, biotechnology, medical device companies and CROs. Striving to high quality, BDM focuses on reducing the time, cost and risk of bringing new pharmaceutical products to market.